 "Dr Reddy's launches anti-ulcer capsules in US")
The drug is the generic equivalent of Zegerid capsules in the US market, having been approved by the US Food and Drug Administration (USFDA).
The Zegerid brand and generic had US sales of approximately $306.7 million for the most recent twelve months ending in May, 2016, the company said citing the IMS Health data.
Zegerid is a registered trademark of Santarus, Inc. a wholly owned subsidiary of Salix Pharmaceuticals, Inc.
The product is used to treat gastric and duodenal ulcers among other related conditions.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app